Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: ANTAGEN BIOSCIENCES INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-07-01 to 2023-06-30
Current total value of award: $299998
Description: THE GOAL OF THE PROPOSED PROJECT IS TO FURTHER DEVELOP ANTAGEN'S NOVEL PROTEIN NANOPARTICLE-BASED EXPRESSION AND DELIVERY SYSTEM USING FCRIDER TECHNOLOGY AND ANTIBODY AFUCOSYLATION TECHNOLOGY TO PRODUCE A2,6-SIALYLATED AFUCOSYLATED ENV-FCRIDER (